Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced an expansion of their partnership to support Provid's preclinical studies of their candidate MS drug, PV-267.
This novel, highly selective small molecule is designed to block a critical step in the autoimmune process of MS, which leads to the destruction of the body's protective myelin in the central nervous system and to the ultimate accumulation of disability.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397